ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives $84.75 Consensus PT from Brokerages

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) have earned an average rating of “Buy” from the ten brokerages that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating on the company. The average 12 month price target among analysts that have covered the stock in the last year is $84.75.

Several equities research analysts recently weighed in on the stock. Guggenheim reiterated a “buy” rating and set a $86.00 price objective on shares of ANI Pharmaceuticals in a research note on Monday, May 12th. HC Wainwright restated a “buy” rating and issued a $93.00 price target (up previously from $84.00) on shares of ANI Pharmaceuticals in a research note on Friday, August 8th. Truist Financial raised their price target on shares of ANI Pharmaceuticals from $65.00 to $77.00 and gave the company a “hold” rating in a research note on Monday, August 11th. Wall Street Zen upgraded shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 16th. Finally, Zacks Research upgraded shares of ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 21st.

Insiders Place Their Bets

In other news, SVP Chad Gassert sold 20,000 shares of the stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $86.97, for a total value of $1,739,400.00. Following the completion of the transaction, the senior vice president directly owned 173,226 shares in the company, valued at $15,065,465.22. This trade represents a 10.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Stephen P. Carey sold 50,000 shares of ANI Pharmaceuticals stock in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $86.07, for a total transaction of $4,303,500.00. Following the completion of the transaction, the chief financial officer owned 180,863 shares in the company, valued at approximately $15,566,878.41. This trade represents a 21.66% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 412,830 shares of company stock valued at $36,382,434. 11.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On ANI Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Envestnet Asset Management Inc. boosted its stake in shares of ANI Pharmaceuticals by 34.2% during the 4th quarter. Envestnet Asset Management Inc. now owns 4,930 shares of the specialty pharmaceutical company’s stock valued at $273,000 after buying an additional 1,256 shares during the period. Stifel Financial Corp lifted its stake in shares of ANI Pharmaceuticals by 20.4% in the 4th quarter. Stifel Financial Corp now owns 8,424 shares of the specialty pharmaceutical company’s stock valued at $466,000 after purchasing an additional 1,425 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in shares of ANI Pharmaceuticals by 20.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,288 shares of the specialty pharmaceutical company’s stock valued at $403,000 after purchasing an additional 1,220 shares during the last quarter. Northern Trust Corp lifted its stake in shares of ANI Pharmaceuticals by 9.0% in the 4th quarter. Northern Trust Corp now owns 204,345 shares of the specialty pharmaceutical company’s stock valued at $11,296,000 after purchasing an additional 16,820 shares during the last quarter. Finally, Ameriprise Financial Inc. lifted its stake in shares of ANI Pharmaceuticals by 14.6% in the 4th quarter. Ameriprise Financial Inc. now owns 271,805 shares of the specialty pharmaceutical company’s stock valued at $15,025,000 after purchasing an additional 34,586 shares during the last quarter. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

ANI Pharmaceuticals Stock Performance

Shares of ANI Pharmaceuticals stock opened at $95.35 on Wednesday. The firm has a market cap of $2.07 billion, a PE ratio of -123.83 and a beta of 0.63. The firm’s 50-day simple moving average is $76.26 and its 200-day simple moving average is $68.25. The company has a debt-to-equity ratio of 1.39, a quick ratio of 1.96 and a current ratio of 2.54. ANI Pharmaceuticals has a 1 year low of $52.50 and a 1 year high of $96.56.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings data on Friday, August 8th. The specialty pharmaceutical company reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.42 by $0.38. The firm had revenue of $211.37 million for the quarter, compared to analyst estimates of $187.18 million. ANI Pharmaceuticals had a negative net margin of 1.37% and a positive return on equity of 25.03%. ANI Pharmaceuticals’s quarterly revenue was up 53.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.02 earnings per share. Equities analysts forecast that ANI Pharmaceuticals will post 3.86 earnings per share for the current fiscal year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.